Sanofi-aventis to build a vaccine facility in China

Published: 28-Nov-2007
Pharmaceutical

Sanofi-aventis is to build a facility to manufacture influenza vaccine in the Shenzhen.


Sanofi-aventis is to build a facility to manufacture influenza vaccine in the Shenzhen.

Sanofi Pasteur, the vaccines division of sanofi-aventis group, plans to start construction of this vaccine manufacturing facility in 2008 with the goal of producing seasonal influenza vaccines for the Chinese market by 2012. This new influenza vaccine facility will be designed for easy expansion to keep pace with the anticipated growth of the Chinese vaccine market.

China is joining a growing number of countries focusing on prevention of diseases and recognising the value of vaccines. The time is right for sanofi pasteur to further invest in China and prepare to provide this fast growing market with the most modern vaccines to be produced in a state of the industry facility,. said Gerard Le Fur, ceo of sanofi-aventis.

The facility will be able to switch to pandemic vaccine manufacturing if a human pandemic influenza is declared and once a pandemic influenza strain is identified by the World Health Organization (WHO).

  • Companies:
  • Sanofi
See more

You may also like

Research & Development

Sanofi to acquire neurodegenerative disease biotech, Vigil Neuroscience for $470m

Read more
The acquisition will boost Sanofi's neurology pipeline — one of its key disease focus areas

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  3. Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
  4. CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
  5. Servier and IDEAYA Biosciences join forces to bring a promising new eye cancer treatment to patients across the globe Servier and IDEAYA Biosciences have entered into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Sanofi to acquire neurodegenerative disease biotech, Vigil Neuroscience for $470m

The acquisition will boost Sanofi's neurology pipeline — one of its key disease focus areas
Ingredients

Therapeutics: nirsevimab for RSV prophylaxis

Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory tract
Finance

Sanofi to acquire Principia Biopharma

The late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases has entered into a definitive agreement with Sanofi
Ingredients

Therapeutics: isatuximab for multiple myeloma

Despite the advances in treatment that have been made in recent years, multiple myeloma blood cancer remains incurable
Manufacturing

Sanofi opens its first digitally enabled continuous manufacturing facility

The biologics manufacturing facility in Framingham, Massachusetts, uses paperless and data-driven manufacturing technologies
Drug Delivery

Sanofi and Abbott partner to integrate glucose sensing and insulin delivery

Collaboration aims to develop tools that combine Abbott’s FreeStyle Libre technology with insulin dosing information for future smart pens, insulin titration apps and cloud software
Manufacturing

Sanofi and Pfizer engage Biovac Institute with vaccines production in South Africa

Facility in Cape Town will start production of Sanofi’s Hexaxim in 2020, and Pfizer’s anti-pneumonia Prevnar 13 in 2021
Subscribe now